# LIS Final QA Review — OpenELIS Reference vs Ozzyl HMS

Date: 2026-07-10
Branch: `abdullah`
Scope: backend, frontend/UI, UI/UX, local middleware, test coverage, E2E readiness, and first hospital deployment risk.

## Executive conclusion

Ozzyl HMS now follows the same broad LIS architecture pattern used by OpenELIS-style analyzer integrations:

```text
Analyzer / vendor PC
→ local bridge / middleware
→ HMS API
→ raw log + mapping + validation + QC + result write + audit + reprocess
```

The system is not a copy of OpenELIS and should not embed OpenELIS as a second runtime. OpenELIS is being used as a reference benchmark only. Ozzyl HMS remains the source of truth.

From the code and tests reviewed, Ozzyl HMS is in a strong MVP-to-production state for small/medium diagnostic LIS bridge use, but final machine safety still depends on site-level raw-message and smoke-test validation for each analyzer model, especially Mindray BC-10/CBC machines.

## OpenELIS reference principles used

OpenELIS/analyzer-bridge patterns emphasize:

- Local bridge on lab PC/server for serial/TCP/file communication.
- ASTM / HL7 / CSV / file-style input support.
- Bridge health/readiness checks.
- Analyzer profile/config discovery.
- Raw message visibility and error dashboard.
- Reprocess after mapping/config fixes.
- QC/control result separation from patient results.
- Site readiness, fallback workflow, and phased go-live.

## Ozzyl HMS implementation reviewed

### Backend

Reviewed/covered areas:

- LIS bridge authentication and allowed route surface.
- Local middleware config generation.
- Bridge heartbeat.
- HL7/ASTM receive paths.
- Analyzer profiles and machine capabilities.
- Machine test mapping.
- Unit conversion factor support.
- Qualitative alias mapping.
- Analyzer result validation gate.
- QC/control analyzer detection.
- QC/Westgard/calibration integration.
- Billing/QC gate before result write.
- Duplicate/corrected result handling.
- Raw result logs.
- Unmatched queue and candidate resolve.
- Reprocess flow.
- Analyzer run grouping.
- Sample storage/referral extension on existing lab workflow.
- Reagent/TAT reconciliation.
- Go-live readiness API.
- Bridge deployment checklist API.
- Stabilization review API.

### Frontend/UI/UX

Reviewed/covered areas:

- Lab Machine Settings page.
- Machine setup capability/profile guidance.
- Mapping table and qualitative aliases.
- Unmatched LIS queue and candidate resolve.
- Message logs.
- Analyzer Runs tab.
- Lab Monitoring Dashboard.
- Analyzer health card.
- Go-live readiness/checklist card.
- Reagent/TAT/exception workflow helpers.

### Local middleware

Reviewed/covered areas:

- Local bridge README and production checklist.
- Queue/retry notes.
- Heartbeat notes.
- HL7 ACK policy.
- Middleware config generation with redacted secrets.

## Important safety controls already present

- Raw analyzer messages are preserved.
- Unknown/unmatched results route to review instead of silent patient write.
- Blocking validation can stop machine result writes.
- QC/control samples are detected before patient order matching.
- Duplicate exact results are skipped.
- Corrected results are tracked.
- Reprocess creates a new `_REPROCESS` log and reuses existing process flow.
- Operator can inspect runs/logs/unmatched records.
- Readiness/checklist/stabilization APIs expose go-live blockers.

## Remaining real-world risks

These cannot be eliminated by software-only tests:

1. **Analyzer-specific protocol mismatch**
   - BC-10 may output HL7, ASTM, serial, vendor-only export, or another format depending on configuration/vendor software.

2. **Barcode/specimen ID mismatch**
   - If the analyzer sends a field different from the HMS barcode/specimen/order number, matching will fail or route to unmatched queue.

3. **CBC code/unit differences**
   - WBC/RBC/HGB/PLT etc. may use machine-specific codes and units. Mapping must be verified from real raw messages.

4. **QC/control marker differences**
   - QC sample identifiers must be confirmed from real analyzer output.

5. **Reagent strict-mode timing**
   - First hospital should start reagent policy in soft mode until result matching and reconciliation are stable.

6. **Current production deployment gap**
   - New readiness/checklist endpoints exist in this branch, but current production returned 404 during read-only E2E because this branch is not deployed yet.

## New E2E coverage added

Added read-only Playwright API smoke tests:

```text
test/e2e/api/lis-readiness.spec.ts
```

Added Playwright project:

```text
lis-readiness
```

Covered live/API-facing checks:

- `/api/lab-monitoring/lis-go-live-readiness`
- `/api/lab-monitoring/lis-bridge-deployment-checklist`
- `/api/lab-monitoring/lis-stabilization-review`
- `/api/lab-machines/capabilities`
- `/api/lab-machines/analyzer-profiles`
- machine-specific runs/logs/middleware-config when a machine exists

The E2E is intentionally read-only and does not POST analyzer results into production. Local Vitest suites cover result-write behavior.

Default behavior: if the target environment has not deployed the new LIS endpoints and returns 404, tests skip.

Deploy verification behavior:

```bash
E2E_REQUIRE_LIS_ENDPOINTS=true pnpm exec playwright test --project=lis-readiness --reporter=list
```

## Verification performed

Backend focused LIS suite:

```text
11 files passed
64 tests passed
```

Root typecheck:

```text
pnpm exec tsc --noEmit
passed
```

Frontend LIS UI suite:

```text
2 files passed
45 tests passed
```

Web typecheck:

```text
cd web && pnpm exec tsc --noEmit
passed
```

E2E discovery:

```text
pnpm exec playwright test --project=lis-readiness --list
3 tests discovered
```

E2E live run against current production:

```text
3 skipped
```

Reason: current production returned 404 for branch-only LIS readiness/capability endpoints. This is expected until this branch is deployed. After deployment, run with `E2E_REQUIRE_LIS_ENDPOINTS=true`.

Full E2E TypeScript project check was attempted but failed due unrelated pre-existing files:

```text
test/e2e/browser/nursing-ui.spec.ts
test/e2e/workflows/reception-full-day.spec.ts
```

Those failures are not caused by the new LIS E2E spec.

## Go/no-go recommendation

### Software branch status

LIS code is ready for controlled merge/deploy from the focused tested scope.

### Deployment status

Do not go live clinically until the first hospital machine bridge passes:

1. Machine interface/protocol confirmation.
2. Raw BC-10/CBC message capture.
3. Test code mapping verification.
4. Unit/conversion verification.
5. QC/control smoke test.
6. Patient/order smoke test.
7. Reprocess/duplicate smoke test.
8. Go-live readiness API with no blockers.
9. First-week monitoring owner assigned.

### Merge blocker

Unrelated dirty workspace files still exist and must be cleaned/reviewed separately before merge/deploy.
